
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health is expected to experience significant growth and profitability in the long term, with their recent inclusion in Unitedhealthcare's commercial coverage plans driving higher price targets from analysts. While they face potential challenges from legal risks and competition, they are investing in new technology and expanding into new markets to drive future growth. Additionally, their strong focus on diversity and sustainability in their workforce positions them well for long-term success. With plans to secure reimbursement for breast cancer and increase adoption of their Shield screening business, they are well-positioned for continued growth and success in the liquid biopsy testing market.
Bears say
Guardant Health is a leader in the liquid biopsy market with strong financial performance in Q1 and a promising pipeline of products and services. However, there are concerns about the sustainability of the company's high prices for its comprehensive genomic profiling (CGP) tests and its potential overreliance on serial testing in the future. Additionally, there are potential risks in the competitive landscape and the accuracy of its CRC testing method.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares